Sign up to save your podcasts
Or
Share Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients
In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.
🔗 Full Study Details: NEJM - EMPA-KIDNEY Study
🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110
Links to the Podcast
#Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits
View all episodes
By Mohammed Al-QadamiIn this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.
🔗 Full Study Details: NEJM - EMPA-KIDNEY Study
🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110
Links to the Podcast
#Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits